Collaboration pairs AtaCor’s investigational extravascular ICD lead with Abbott’s investigational extravascular ICD system to deliver potentially life-saving therapies
AtaCor plans to initiate a pivotal Investigational Device Exemption (IDE) clinical trial in 2026 to evaluate the investigational extravascular implantable cardioverter defibrillator (EV-ICD) system
This initiative furthers Abbott’s leadership in advancing next-generation cardiac rhythm management solutions that expand options for physicians to treat people with irregular heart rhythms
Abbott Park, Ill., Jan. 12, 2026 — Abbott today announced a collaboration with AtaCor Medical to advance a next-generation investigational extravascular implantable cardioverter defibrillator (EV-ICD) system designed to deliver defibrillation therapy to people with life-threatening heart rhythms.
AtaCor is a cardiac rhythm management (CRM) company developing extravascular defibrillation technologies designed to reduce risks associated with traditional ICDs. Through the collaboration, AtaCor’s investigational parasternal EV-ICD lead (Atala™) will be paired with Abbott’s investigational ICD system.